Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PI 2620

Next Previous
Drug Profile

PI 2620

Alternative Names: [18F]PI-2620; PI-2620; Tau-PET tracer - AC Immune

Latest Information Update: 28 Dec 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AC Immune
  • Developer AC Immune; Life Molecular Imaging; The Michael J. Fox Foundation for Parkinson's Research; University of Pennsylvania
  • Class 3-ring heterocyclic compounds; Fluorinated hydrocarbons; Imaging agents; Pyridines; Pyrroles; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Corticobasal degeneration; Progressive supranuclear palsy
  • New Molecular Entity No

Highest Development Phases

  • Phase III Alzheimer's disease; Dementia
  • Phase II Parkinson's disease; Progressive supranuclear palsy
  • Phase I Traumatic brain injuries

Most Recent Events

  • 28 Dec 2023 No recent reports of development identified for phase-I development in Alzheimer's-disease(Diagnosis) in Germany (IV, Injection)
  • 28 Dec 2023 No recent reports of development identified for phase-I development in Progressive-supranuclear-palsy(Diagnosis) in Germany (IV, Injection)
  • 27 Jun 2023 Genentech completes a phase I trial in Alzheimer's disease (Diagnosis) in USA (NCT04566003)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top